Pancreatic cancer remains one of the most challenging cancers to treat, largely because it’s often diagnosed at a late stage when treatment options are limited. Now, a new blood test developed by researchers at the University of Pennsylvania and the Mayo Clinic offers a potential path toward earlier detection, a critical step in improving outcomes for this aggressive disease. The test, detailed in the journal Clinical Cancer Research, combines existing and newly identified biomarkers to identify pancreatic cancer with improved accuracy, even in its earliest stages.
Currently, only about 10% of patients with pancreatic cancer are alive five years after diagnosis, according to the American Cancer Society. This low survival rate is largely attributed to the difficulty in detecting the cancer early, as symptoms are often vague and non-specific. A reliable screening tool for those at higher risk could significantly alter this trajectory, and this new blood test represents a promising step in that direction.
The research team focused on identifying proteins in the blood that are elevated in individuals with pancreatic cancer. While existing biomarkers like carbohydrate antigen 19-9 (CA19-9) are used to monitor treatment response, they aren’t reliable for early detection. CA19-9 levels can be elevated in other, non-cancerous conditions, such as pancreatitis and bile duct obstruction, and not all individuals produce this marker due to genetic factors. Similarly, thrombospondin 2 (THBS2) has shown promise but too has limitations as a standalone screening tool.
Identifying New Clues in the Blood
To overcome these challenges, the researchers analyzed stored blood samples from individuals both with and without pancreatic cancer. Their analysis revealed two additional proteins – aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR) – that consistently showed elevated levels in patients with early-stage pancreatic cancer. These proteins appear to be more specific to the disease than previously studied markers.
“By adding ANPEP and PIGR to the existing markers, we’ve significantly improved our ability to detect this cancer when it’s most treatable,” said Kenneth Zaret, Ph.D., the lead investigator from the University of Pennsylvania’s Perelman School of Medicine. The combination of all four biomarkers – CA19-9, THBS2, ANPEP, and PIGR – demonstrated a high degree of accuracy. The test correctly identified pancreatic cancer in 91.9% of cases across all stages, with a false positive rate of 5% in individuals without the disease. Importantly, it detected 87.5% of early-stage (stage I/II) cancers.
Distinguishing Pancreatic Cancer from Other Conditions
A key advantage of this new test is its ability to differentiate pancreatic cancer from other conditions that can cause similar symptoms, such as pancreatitis. Here’s crucial because misdiagnosis can lead to unnecessary anxiety and potentially inappropriate treatment. The researchers found that the four-marker panel was better at distinguishing between these conditions than relying on individual biomarkers alone.
This improved specificity is particularly critical given the challenges in diagnosing pancreatic cancer. Symptoms like abdominal pain, jaundice, and weight loss can be indicative of a variety of health issues, making it difficult for doctors to pinpoint the cause. A more accurate blood test could help streamline the diagnostic process and ensure that patients receive the appropriate care more quickly.
What’s Next for the Test?
While the results of this retrospective study are encouraging, further research is needed before the test can be widely implemented as a screening tool. The researchers plan to conduct larger, prospective studies to evaluate the test’s performance in individuals *before* they develop symptoms – so-called “prediagnostic” studies. These studies will be crucial in determining whether the test can effectively identify high-risk individuals who would benefit from earlier monitoring and intervention.
Zaret explained that these future studies will focus on individuals with known risk factors for pancreatic cancer, such as a family history of the disease, genetic predispositions, or a history of pancreatic cysts or pancreatitis. Penn Medicine News reported that the team is actively seeking funding and partnerships to support these larger-scale trials.
The study was supported by several grants from the National Institutes of Health (NIH), including U01CA210138, P50CA102701, S10 OD023586-01, P30 DK020579, UL1 TR002345, P30CA091842, and U01CA210138.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The development of this new blood test offers a beacon of hope in the fight against pancreatic cancer. As research progresses and larger studies are completed, it may become a valuable tool for early detection and improved outcomes for those at risk of this devastating disease. The next major step will be the initiation of these prospective studies, which are expected to initiate within the next year, according to researchers involved in the project.
Have thoughts on this new development? Share your comments below, and please consider sharing this article with your network.
Related reading
